BetterLife Pharma (BETRF) Long-Term Deferred Tax (2013 - 2019)
BetterLife Pharma (BETRF) posted quarterly Long-Term Deferred Tax of $1.6 million for Q1 2019, down 79.26% year-over-year from $7.8 million in Q1 2018, and down 79.26% quarter-over-quarter from $7.8 million in Q1 2018.
BetterLife Pharma (BETRF) Long-Term Deferred Tax (2013 - 2019) Analysis & Trends
BetterLife Pharma's Long-Term Deferred Tax history runs 4 years deep, the most recent figure standing at $1.6 million for Q1 2019.
- In Q1 2019, Long-Term Deferred Tax fell 79.26% year-over-year to $1.6 million; the TTM figure through Jan 2019 stood at $1.6 million (down 79.26% YoY), while the FY2019 annual figure was $1.7 million, down 78.81% from the prior year.
- Long-Term Deferred Tax for Q1 2019 stood at $1.6 million, down from $7.8 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $7.8 million in Q1 2018, with the low at $1.6 million in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | BetterLife Pharma | 36.45 Mn | 36.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2019 | 1.63 Mn |
| Jan 31, 2018 | 7.85 Mn |
| Jan 31, 2014 | 595,060.84 |
| Jan 31, 2013 | 444,278.17 |